Vascular Biogenics Ltd. (NASDAQ:VBLT) Expected to Announce Earnings of -$0.10 Per Share

Brokerages predict that Vascular Biogenics Ltd. (NASDAQ:VBLT) will report earnings per share (EPS) of ($0.10) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Vascular Biogenics’ earnings, with estimates ranging from ($0.12) to ($0.09). Vascular Biogenics reported earnings of ($0.14) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 28.6%. The business is scheduled to issue its next quarterly earnings report on Thursday, August 12th.

On average, analysts expect that Vascular Biogenics will report full year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.56) to ($0.40). For the next year, analysts forecast that the firm will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.55) to ($0.37). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Vascular Biogenics.

Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Monday, May 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.01. Vascular Biogenics had a negative net margin of 2,692.41% and a negative return on equity of 61.77%.

A number of brokerages have commented on VBLT. HC Wainwright lifted their target price on Vascular Biogenics from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Thursday, January 28th. Zacks Investment Research lowered Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 30th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PVG Asset Management Corp bought a new position in Vascular Biogenics in the 1st quarter worth approximately $53,000. Bank of New York Mellon Corp acquired a new position in Vascular Biogenics during the 4th quarter worth $47,000. HBK Sorce Advisory LLC acquired a new position in Vascular Biogenics during the 1st quarter worth $44,000. Vident Investment Advisory LLC grew its stake in shares of Vascular Biogenics by 50.0% in the first quarter. Vident Investment Advisory LLC now owns 22,950 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 7,650 shares in the last quarter. Finally, Koshinski Asset Management Inc. bought a new position in shares of Vascular Biogenics in the fourth quarter valued at approximately $421,000. 4.50% of the stock is currently owned by institutional investors.

Shares of NASDAQ:VBLT opened at $1.98 on Tuesday. The company has a market cap of $95.41 million, a PE ratio of -3.47 and a beta of 1.17. Vascular Biogenics has a fifty-two week low of $1.01 and a fifty-two week high of $3.17. The firm has a 50-day simple moving average of $1.95 and a 200 day simple moving average of $1.91.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

See Also: How does new data get added to a blockchain?

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.